Skip to main content

BeiGene's Anti-PD-1 Approved in China for 4th and 5th Indications

BeiGene, a Beijing biotech, reported its anti-PD-1 antibody tislelizumab has been approved in China for two new indications, bringing the total to five. The new indications are first-line treatment for advanced non-squamous non-small cell lung cancer and conditional approval as a second-line therapy for hepatocellular carcinoma. In China , tislelizumab in now approved for lung, liver, bladder and lymphoma cancers. Earlier this year, BeiGene out-licensed global ex-China rights for tislelizumab to Novartis in a $2.2 billion agreement. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) (NYSE: NVS) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.